Administration of recombinant versions of endogenous plasma proteins is a common therapeutic approach to hematological and inflammatory disorders, but can be expensive, immunogenic and associated with undesirable side-effects.
Our research group seeks to address these deficiencies by generating enhanced recombinant therapeutics through innovative bioengineering of existing plasma proteins and cellular receptors.
We are particularly interested in the protein C pathway, whose multiple roles in anticoagulant, antifibrinolytic and anti-inflammatory pathways provide opportunities to develop new agents with the potential to modify these processes for therapeutic effect.
To date, the group has developed a number of unique recombinant protein variants with enhanced functional properties and significant therapeutic potential. These novel drug candidates have been created via manipulation of enzymatic activity, protein interactions, substrate recognition and post-translational modification. Ultimately, our research aims to develop new treatment approaches for inflammatory, haemostatic and malignant diseases.